Investment Advisor, S P Tulsian feels that Alpa Laboratories is a mediocre type of issue and it won't give too much of listing gains.

Tulsian told CNBC-TV18, "Alpa Laboratories is an API company on the job basis for the others plus they have their own formulations. The profitability is reasonable. They have 7-8 products in which they are expanding their capacity from 100% to 400% in the capsules, tablets and all that."

He added, "They have lined up a capex of about Rs 75 crore, partly it is coming from a term loan of Rs 20 crore. Again a mediocre type of issue you are getting a PE multiple of 11-12-13 and nothing exciting so that won't give you too much of the listing gain or even if you remain invested for 3-6 months."